ArriVent Posts $40.3M Q3 Loss, $393.2M Cash to Mid-2028; R&D Chief Lutzker to Retire
AVBP sits 25% above its 52-week low of $11.36.
Summary
ArriVent reported a $40.3M Q3 net loss and $393.2M in cash it says funds operations to mid-2028, while announcing R&D chief and co-founder Stuart Lutzker will retire December 1 with CMO Priti Patel taking over R&D.
Key Events · Earnings and Guidance · AVBP
-
Q3 Loss Widens, Runway Extended
Net loss was $40.3M ($0.81 per share) for Q3 2026 versus $34.98M a year ago; nine-month net loss was $133.5M versus $130.8M.
-
Cash Funds Operations to Mid-2028
Cash and investments totaled $393.2M at September 30, 2026, which the company expects to fund operations to mid-2028.
-
R&D Chief Lutzker to Retire
Co-founder and President of R&D Stuart Lutzker retires effective December 1, 2026, receiving a one-time $428,438.21 payment; no disagreement with the company was cited.
-
CMO Patel Takes Over R&D
Chief Medical Officer Priti Patel assumes leadership of the R&D function effective December 1, 2026.
Analysis · AVBP · Life Sciences
The quarter itself is unremarkable — the net loss widened to $40.3M from $35.0M a year ago and R&D spend was roughly flat. What matters is the runway: $393.2M in cash and investments is now guided to fund operations to mid-2028, roughly 18 months out from today, which buys time to sort out firmonertinib after the October FURVENT failure. The leadership change is the second piece: co-founder and R&D head Stuart Lutzker, who built the ADC pipeline, retires December 1 and CMO Priti Patel takes over R&D — a $428,438.21 one-time payment covers the transition. Investors get a firmonertinib update in Q1 2027 and ARR-217 Phase 1b data in H1 2027.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVBP was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $698.2M. The 52-week trading range was $11.36 to $35.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.